CA-CAVLI-WIRELESS
5.1.2023 15:08:41 CET | Business Wire | Press release
Cavli Wireless, one of the first truly 'IoT ready' cellular module manufacturers, and Qualcomm Technologies. Inc., the world’s leading wireless technology innovator, announced today a strategic collaboration for LTE CAT1 technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005571/en/
Powering the next generation of CAT1.bis IoT with Cavli C16QS Smart Cellular IoT Module (Graphic: Business Wire)
By utilizing the Qualcomm® QCX216 LTE IoT Modem, Cavli Wireless will now be able to utilize the pioneering speed and innovative solutions that Qualcomm Technologies is known for, and deliver the Cavli Hubble IoT stack to customers worldwide. With the C16QS CAT1.bis Cellular IoT module, Cavli Wireless will make IoT adoption seamless & scalable for a wide range of IoT use cases ranging from e-mobility, POS machines, Electric charging stations, TCU, Asset tracking, and so much more.
The Cavli C16QS is an integrated single-mode LTE CAT1.bis Cellular Module based on 3GPP Release 14 comes with integrated eSIM and GNSS. The Cavli C16QS will also offer OEMs implementing IoT to cut down initial hardware costs due to the sub $5 pricing of the module. And further combining the IoT hardware along with Cavli Hubble - The world's most robust IoT connectivity and modem management platform, the C16QS will offer unparalleled value for all industries across all borders.
In addition, under the Hubble Stack Intelligence, the Cavli C16QS can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble Modem Management platform wherein a customer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
“Customer samples are available now, and mass production will start in early 2023 at the India facility.”
“The launch of C16QS LTE CAT1.bis cellular IoT module is a new and exciting beginning to our collaboration with Qualcomm Technologies,” said John Mathew, Chief Executive Officer at Cavli Wireless. “We are beyond excited to have our new module be introduced to the global markets, which will be the start of the new era of LTE CAT1 for IoT. This is another big step for Cavli Wireless in moving forward with our vision of democratizing IoT for all.”
About Cavli Wireless
Cavli Wireless designs and manufactures IoT-Ready cellular modules that improve device reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated
Qualcomm QCX216 LTE IoT Modem is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release
The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom